1	[Settlement of Lawsuit - Richard S. Sackler, et al City to Receive \$8,000,000 to \$12,000,000 Over 15 Years]
2	
3	Ordinance authorizing the partial settlement of the lawsuit filed on behalf of the City
4	and County of San Francisco and the People of the State of California against, inter
5	alia, Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler,
6	llene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the
7	Benefit of Members of the Raymond Sackler Family (collectively, "Sacklers") for
8	abatement funds in the range of \$8,000,000 to \$12,000,000 to be paid over 15 years; the
9	lawsuit was filed on December 18, 2018, in the United States District Court for the
10	Northern District of California, Case No. 3:18-cv-7591-CRB-JSC; entitled The City and
11	County of San Francisco and the People of the State of California v. Purdue Pharma
12	L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler,
13	Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the
14	Benefit of Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P.,
15	Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc.,
16	Endo International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Jansser
17	Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC,
18	Allergan Plc F/K/A Actavis Plc, Watson Pharmaceuticals, Inc. N/K/A Actavis, Inc.,
19	Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. F/K/A/ Watson Pharma,
20	Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson
21	Corporation; the lawsuit involves allegations that Purdue and the Sacklers contributed
22	to the opioid crisis in San Francisco by incentivizing the sale and use of opioids
23	despite knowledge of the growing epidemic caused by opioid misuse.
24	Be it ordained by the People of the City and County of San Francisco:

25

Section 1. Pursuant to Charter Section 6.102(5), the Board of Supervisors hereby
authorizes the City Attorney to partially settle the action entitled The City and County of San
Francisco and the People of the State of California v. Purdue Pharma L.P. et al., United
States District Court for the Northern District of California, Case No. 3:18-cv-7591-CRB-JSC,
by the payment of abatement funds from Richard S. Sackler, Jonathan D. Sackler, Mortimer
D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler,
David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler Family collectively
to San Francisco, in an amount estimated to be between \$8 million and \$12 million over the
next 15 years. The lawsuit involves allegations that the Sacklers created a public nuisance
and violated the Unfair Competition Law and the False Advertising Laws by incentivizing the
sale and use of opioids despite knowledge of the growing epidemic caused by opioid misuse.
Section 2. The above-named action was filed in the United States District Court for the
Northern District of California on December 18, 2018, and the following parties were named in
the lawsuit: The City and County of San Francisco and the People of the State of California,
as plaintiffs; Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A.
Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A.
Sackler, Trust for the Benefit of Members of the Raymond Sackler Family, Rhodes
Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva
Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo
Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt
Plc, Mallinckrodt LLC, Allergan Plc F/K/A Actavis Plc, Watson Pharmaceuticals, Inc. N/K/A
Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. F/K/A/ Watson
Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson
Corporation as defendants.

1		APPROVED AS TO FORM AND RECOMMENDED:
2		
3		/s/ Sara J. Eisenberg SARA J. EISENBERG
4		SARA J. EISENBERG Chief of Complex and Affirmative Litigation
5		
6		
7	n:\cpu\li2021\190034\01558702.docx	
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		